Last updated: December 6, 2025
Executive Summary
Fulphila (pegfilgrastim-jmdb), a biosimilar of Neulasta, has carved a significant niche in the oncology and hematology markets combating neutropenia, specifically febrile neutropenia in chemotherapy patients. While Fulphila itself is not a direct competitor, understanding its market dynamics, pricing strategies, and competitive landscape offers critical insights for similar biologic agents targeting uric acid reduction—particularly pegloticase (Krystexxa), utilized in chronic gout. This analysis explores Fulphila’s market positioning, pricing strategies, revenue potential, and projections considering the context of biologic pricing, biosimilar penetration, and regulatory factors.
1. Overview of Fulphila (Pegfilgrastim-Jmdb)
Product Profile
- Indications: Febrile neutropenia prophylaxis in patients receiving myelosuppressive chemotherapy.
- Approval Date: June 2018 (FDA)
- Manufacturers: Mylan and Biocon, developed as a biosimilar to Amgen’s Neulasta.
- Manufacturing Details: Biosimilar status influences pricing to promote market penetration against the originator.
Market Landscape
- Market Size (Neutropenia Prophylaxis): Estimated at $4.2 billion globally in 2022, with growth driven by expanding chemotherapy indications.
- Market Penetration: Biosimilars commanding approximately 30-40% in US and European markets by 2022, driven by price competition.
- Key Competitors: Neulasta (Amgen), Neulasta Onpro, and other biosimilars like Udenyca (coherus) and Ziextenzo (Sandoz).
2. Epidemiological and Market Drivers
Patient Population
| Parameter |
Estimate |
Source/Comment |
| Annual cancer diagnoses (US, 2022) |
1.9 million |
[2] |
| Patients receiving chemotherapy requiring neutropenia prophylaxis |
20-25% of chemo patients |
Clinical guidelines |
| US market for pegfilgrastim |
~480,000 treatments annually |
Based on prescription trends |
Market Growth Factors
- Rising cancer incidence rates globally, especially lung, breast, and colorectal cancers.
- Broader adoption of biosimilars driven by policy shifts and cost-saving initiatives.
- COVID-19 pandemic-induced delays affecting some treatment timelines but increasing emphasis on prophylactic measures.
3. Price Strategies and Market Penetration
Pricing Analysis
| Product |
Title List Price (Per Dose, USD) |
Approximate Discounted Price after Biosimilar Entry (USD) |
Market Share Post-Entry |
Remarks |
| Neulasta (Originator) |
~$8,000 |
N/A |
Dominant pre-2018 |
High brand loyalty; high cost |
| Fulphila (biosimilar) |
~$6,300 |
$3,500–$4,500 |
Growing to ~40% in US |
Price competition to gain market share |
| Udenyca |
~$7,200 |
Similar range |
Niche but growing |
Competitive biosimilar effort |
Note: Biosimilar prices typically reflect discounts of 30-50% over originators with further reductions in institutional contracts.
Prescribing Trends
- Initial Hesitance: Clinicians skeptical about biosimilar efficacy and safety.
- Growing Acceptance: Post-approval clinical data and policy pushes favor biosimilar use.
- Switching Strategies: Focused on cost savings without compromising outcomes.
4. Revenue Projections for Fulphila
Historical Revenue Data
| Year |
Estimated Revenue (USD millions) |
Commentary |
| 2019 |
~$100 |
Early market penetration; initial uptake |
| 2020 |
~$350 |
Increased adoption; expansion of indications |
| 2021 |
~$580 |
Growing market share, biosimilar momentum |
| 2022 |
~$700 |
Stabilization of market presence |
Forecasted Revenue (2023-2027)
| Year |
Projected Revenue (USD millions) |
Assumptions |
| 2023 |
$750–$850 |
Increased biosimilar acceptance, expanding indications, continued competition |
| 2024 |
$800–$950 |
Market maturation, possible price stabilization, or reduction |
| 2025 |
$850–$1,100 |
Potential further penetration, international expansion |
| 2026 |
$900–$1,200 |
Broader rollout, policy-driven demand |
| 2027 |
$950–$1,300 |
Slight growth plateau expected |
Key Market Risks & Opportunities
| Risks |
Opportunities |
| Price erosion due to biosimilar competition |
Cost savings for healthcare systems |
| Prescriber hesitance |
Growing clinician familiarity and confidence |
| Regulatory delays |
Potential for label expansion or new indications |
5. How Does Fulphila Compare to Pegloticase (Krystexxa)?
| Aspect |
Fulphila |
Pegloticase (Krystexxa) |
| Indication |
Febrile neutropenia prophylaxis |
Chronic refractory gout |
| Market Size |
Larger, with hundreds of thousands of annual treatments |
Smaller; specialty niche (~3,000-4,000 annually in US) |
| Pricing |
~$4,000–$6,000 per dose (biosimilar pricing) |
~$23,000 per infusion (original) |
| Biosimilar Status |
Yes |
No (patented biologic) |
| Entry Timeline |
2018 |
Approved in 2010; no biosimilar yet |
Pricing Projections for Pegloticase
Given the rarity of gout cases requiring pegloticase and its status as an orphan biologic, pricing trends are expected to remain relatively stable or decrease marginally due to biosimilar development if approved.
6. Regulatory and Policy Environment
Biosimilar Policies
- US FDA: Approved multiple biosimilars; mandates and incentivization programs favor biosimilar uptake.
- European EMA: Pioneered biosimilar regulations, with biosimilars accounting for a significant proportion of biologics in the EU.
- Pricing & Reimbursement: Policies in the US vary by payer; Medicare and private insurers emphasize cost reduction.
Pricing Regulations
- US: No federal cap; market-driven pricing with discounts.
- EU: Price negotiations with governments often lead to significant discounts (~30-50%).
7. Comparative Analysis of Biosimilar Pricing Strategies
| Biosimilar |
Launch Year |
Price Discount vs. Originator |
Market Share (2022) |
Strategies of Manufacturer |
| Fulphila |
2018 |
30-50% |
~40% in US |
Aggressive pricing, extensive formulary placement |
| Udenyca |
2020 |
35-45% |
Growing |
Focus on provider education |
| Ziextenzo |
2019 |
~40% |
Moderate |
Collaborative contracting |
8. Key Factors Influencing Future Pricing & Market Share
| Factor |
Impact |
| Biosimilar market entry of additional competitors |
Potential downward pressure on prices |
| Payer negotiations |
Further discounts or formulary exclusions |
| Clinical innovation & new indications |
Expansion of use, stabilization of prices |
| Policy incentives |
Accelerate biosimilar adoption |
9. FAQs
Q1: What are the main drivers influencing Fulphila’s market share?
A: Efficacy equivalence to originator, clinician confidence in biosimilars, payer policies favoring cost savings, and aggressive formulary strategies are major drivers.
Q2: How do biosimilar prices compare to the original biologic?
A: Biosimilars typically retail at 30-50% savings over originator biologics, with some discounts exceeding 50% due to market competition and reimbursement strategies.
Q3: What are the key regulatory factors affecting biosimilar pricing?
A: Regulatory approval timelines, interchangeability designations, and patent litigation influence market entry and pricing strategies.
Q4: How might global trends impact Fulphila’s pricing?
A: Large markets like Europe and Asia demonstrate increasing biosimilar adoption, potentially pressuring US pricing and encouraging global price convergence.
Q5: Are there specific policies impacting biologic or biosimilar pricing in the US?
A: Yes. The Inflation Reduction Act and Centers for Medicare & Medicaid Services policies aim to promote biosimilar use and reduce drug costs via formulary management and reimbursement incentives.
10. Key Takeaways
- Market Dynamics: Biosimilar penetration is steadily increasing, leading to significant price competition for biologics like Fulphila.
- Pricing Trends: Biosimilars are generally discounted 30-50% relative to originators; further discounts are driven by market competition and formulary negotiations.
- Revenue Outlook: Fulphila’s revenues are projected to grow modestly through 2027, stabilizing as market saturation is approached.
- Policy Impact: Regulatory incentives, government policies, and healthcare system initiatives critically shape both pricing and market share.
- Strategic Consideration: For biologics combating gout, such as pegloticase, biosimilar development and pricing policies will likely mirror these trends, impacting cost, accessibility, and reimbursement landscape.
References
[1] Market Research Future. "Global Biosimilars Market Trends and Projections 2022."
[2] American Cancer Society. "Cancer Facts & Estimates 2022."
[3] EvaluatePharma. "Top Pharmaceutical Brands and Revenue Data."
[4] US FDA. "Biosimilar Approval Pathway and Policy."
[5] Centers for Medicare & Medicaid Services (CMS). "Biosimilar Coverage Policies."
